Nightingale Health’s Annual Report for financial year 2023–2024 has been published
Nightingale Health Plc
Company release
10 October 2024 at 09:00 a.m. (EEST)
Nightingale Health Plc’s Annual Report for financial year 1 July 2023–30 June 2024 has been published. The publication includes the Board of Directors' Report, the Consolidated and Parent Company Financial Statements, the Corporate Governance Statement, and the Remuneration Report.
The Annual Report, the Corporate Governance Statement, and the Remuneration Report are attached to this release and are also available on Nightingale Health’s website at https://ir.nightingalehealth.com/.
For further information, please contact:
Teemu Suna, CEO
Certified Adviser:
Oaklins Merasco Ltd. tel. +358 9 6129 670
About Nightingale Health
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
Attachments
Annual Report 2023–2024
Corporate Governance Statement 2023–2024
Remuneration Report 2023–2024
